Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252383 | 0.86 | KDM4E (0.64) | MAP2KDM4EALDH1A1HPGDGAA | |
| SCHEMBL7229483 | 0.81 | KDM4E (0.66) | MAP2KDM4EALDH1A1HPGDGAA | |
| SCHEMBL7231941 | 0.80 | ESR1 (0.62) | MAP2KDM4EALDH1A1HPGDPTGS2 | |
| SCHEMBL6252220 | 0.79 | KDM4E (0.55) | MAP2KDM4EALDH1A1HPGDGAA | |
| SCHEMBL6254670 | 0.79 | MAP2 (0.56) | MAP2KDM4EALDH1A1HPGDCA1 | |
| SCHEMBL6256115 | 0.76 | CCR6 (0.51) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL61857 | 0.75 | MAP2 (0.62) | MAP2KDM4EALDH1A1HPGDGAA | |
| SCHEMBL6257903 | 0.75 | PTGS2 (0.59) | KDM4EPTGS2ESR1ESR2MAPT | |
| SCHEMBL6253981 | 0.75 | PTGS2 (0.59) | KDM4EPTGS2ESR1ESR2MAPT | |
| SCHEMBL27443531 | 0.75 | MAP2 (0.61) | MAP2KDM4EALDH1A1HPGDCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN INC. | 2002-02-07 | — | — | US | claimed |
| EP-0831809-A4 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN INC (US) | 2001-11-28 | — | — | EP | claimed |
| US-6090838-A | USING 2,5-BISINDOL-3-YL-1,4-QUINONE | SUGEN, INC. (US) | 2000-07-18 | — | — | US | claimed |
| EP-0831809-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | Sugen, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040115-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6750240-B2 | FORMING 2,5-DIHYDROXY-3,6-DI(2-(3-METHYL-N-BUTYL)INDOL-3-YL)-1,4-QUINONE BY REACTING 2,3,5,6-TETRABROMO-1,4-BENZOQUINONE WITH 2-(3-METHYL-N-BUTYL)INDOLE IN PRESENCE OF CESIUM CARBONATE; ANTICANCER AGENTS | SUGEN, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6660763-B2 | Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy | SUGEN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030060635-A1 | Methods of using bis-indolylquinones | TANG PENG C (US) | 2003-03-27 | — | — | US | disclosed |
| US-20020156116-A1 | Bis-indolyquinone compounds | TANG PENG CHO (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6376529-B1 | INSULIN DISEASES; ANTIDIABETIC AGENTS | SUGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6239161-B1 | 2,5-DIHYDROXY-3,6-DI-(INDOL-3-YL)-QUINONE DERIVATIVES; ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | SUGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6110957-A | ANTITUMOR AGENT TREATING CELL PROLIFERATIVE DISORDERS SUCH AS CANCER, DYES, FUNGICIDES, BACTERICIDES | SUGEN, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6090838-A | USING 2,5-BISINDOL-3-YL-1,4-QUINONE | SUGEN, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5780496-A | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0831809-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | Sugen, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040115-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156116-A1 | Bis-indolyquinone compounds | IRS1, GRK2, GID4 | MAP2 1159/4885KDM4E 3407/4885ALDH1A1 4519/4885 |
| US-20030060635-A1 | Methods of using bis-indolylquinones | IDO2, IDO1, IPO5 | MAP2 495/4885KDM4E 1821/4885ALDH1A1 2437/4885 |
| US-20020016353-A1 | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | GRB2, NCK1, ABL1 | MAP2 678/4885KDM4E 1378/4885ALDH1A1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.